Welcome
Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is a leader in the discovery and development of novel RNAi-based therapeutics. Quark has a fully integrated drug development platform.

QUARK is conducting  clinical studies in the areas of acute kidney injury associated with major cardiovascular surgery, delayed graft function in kidney transplantation and non-arteritic anterior ischemic...
Read More>
 
PF-655 (formerly REDD14NP and RTP801i) is a synthetic siRNA designed to inhibit the expression of Quark’s proprietary target, RTP801....
Read More>

QPI-1002 (I5NP) is a synthetic siRNA designed to temporarily inhibit expression of the pro-apoptotic protein, p53. Its development is...
Read More>

Development Pipeline...
Read More>
 
8/18/2010
Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
 
7/15/2010
Nitto Denko and Quark Pharmaceuticals to Enter into Collaboration to Develop a Novel siRNA Anti-fibrotic Drug
More News >
Web Development HomeProductsContact ©2007 Quark Pharmaceuticals, Inc.